COVID-19 vacine targeting SARS-CoV-2 spike protein RBM (Neovii)

N/A

Report date: 2025/01/26 19:30:19

Base Information

Drug NameCOVID-19 vacine targeting SARS-CoV-2 spike protein RBM (Neovii)

Drug Alias NameCOVID-19 vacine targeting SARS-CoV-2 spike protein RBM (Tel Aviv University/Ramot)SARS-CoV-2 protein subunit vaccine(Tel Aviv University/Ramot/Neovii)SARS-CoV-2 protein subunit vaccine (Tel Aviv University/Ramot/Neovii)

ClassificationVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Application > Prophylactic vaccine

Mechanisms of ActionCoronavirus spike glycoprotein modulators

TargetsCoronavirus spike glycoprotein

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTel Aviv University

China Registration ClassN/A

Develop Information

Active CompaniesI-Pharm

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A